Merck
CN
  • Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients.

Thiamine deficiency and unexplained encephalopathy in hemodialysis and peritoneal dialysis patients.

American journal of kidney diseases : the official journal of the National Kidney Foundation (2001-10-31)
S C Hung, S H Hung, D C Tarng, W C Yang, T W Chen, T P Huang
ABSTRACT

Patients with end-stage renal disease undergoing regular dialysis are prone to encephalopathy, but the cause is often unclear. Dialysis patients are at risk for thiamine deficiency, which may mimic many uremic complications, including encephalopathy. To determine whether unexplained encephalopathy in regular dialysis patients is associated with thiamine deficiency, we conducted a prospective study that enrolled 30 consecutive dialysis patients with altered mental status admitted to a referred hospital during a 1-year period. A complete history, physical and neurological examinations, laboratory investigations, and computed tomographic scans or magnetic resonance imaging of the brain were obtained for each subject. In 10 of the 30 patients, diagnoses remained obscure after the initial workup. Manifestations included confusion, chorea, acute visual loss, rapidly progressive dementia, myoclonus, convulsions, and coma. Intravenous thiamine was administered to these 10 patients. All 10 patients had thiamine deficiency confirmed by a marked response to thiamine supplementation and/or a low serum thiamine concentration (35.3 +/- 6.0 nmol/L; normal, >50 nmol/L). Nine patients recovered, but one patient failed to respond because of delayed treatment. We conclude that in regular dialysis patients, unexplained encephalopathy can be mainly attributed to thiamine deficiency. This condition is fatal if unrecognized and can be successfully treated with prompt thiamine replacement.

MATERIALS
Product Number
Brand
Product Description

Supelco
Glycolic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
Oxalic acid concentrate, 0.1 M (COOH)2 (0.2N), eluent concentrate for IC
Sigma-Aldrich
Oxalic acid, purified grade, 99.999% trace metals basis
Sigma-Aldrich
Retinol, BioXtra, ≥97.5% (HPLC), ~3100 U/mg
Supelco
trans-4-Hydroxy-L-proline, analytical standard
Sigma-Aldrich
p-Cresol, 99%
Sigma-Aldrich
Oxalic acid, ReagentPlus®, ≥99%
Sigma-Aldrich
Glycolic acid, ReagentPlus®, 99%
Supelco
4-Methylphenol solution, certified reference material, 5000 μg/mL in methanol
Sigma-Aldrich
Phthalic acid, puriss. p.a., ≥99.5% (T)
Sigma-Aldrich
Retinol, ≥95.0% (HPLC), ~2700 U/mg
Sigma-Aldrich
Phthalic acid, reagent grade, 98%
Sigma-Aldrich
Glycolic acid solution, high purity, 70 wt. % in H2O
Sigma-Aldrich
p-Cresol, ≥99%, FG
Sigma-Aldrich
trans-4-Hydroxy-L-proline, ≥99%
Sigma-Aldrich
Oxalic acid, 98%
Sigma-Aldrich
Phthalic acid, ACS reagent, ≥99.5%
Sigma-Aldrich
Glycolic acid solution, technical grade, 70 wt. % in H2O
Sigma-Aldrich
Betaine solution, 5 M, PCR Reagent
Sigma-Aldrich
Glycolic acid, BioXtra, ≥98.0% (titration)
Supelco
p-Cresol, analytical standard
Sigma-Aldrich
Oxalic acid, puriss. p.a., anhydrous, ≥99.0% (RT)
Sigma-Aldrich
trans-4-Hydroxy-L-proline, BioXtra, ≥99.0% (NT)
Sigma-Aldrich
Retinol, synthetic, ≥95% (HPLC), (Powder or Powder with Lumps)
Sigma-Aldrich
trans-4-Hydroxy-L-proline, Vetec, reagent grade, 99%
Sigma-Aldrich
L-Proline, Vetec, reagent grade, ≥99%
Sigma-Aldrich
L-Proline, ReagentPlus®, ≥99% (HPLC)
Supelco
L-Proline, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Proline, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Zinc, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.9%, granular